Search
Irinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigational[A263376] Approved by the FDA in 1996,[A263366] irinotecan is used to treat colorectal cancer and pancreatic adenocarcinoma. … This leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376]
Glycopyrronium
go.drugbank.com/drugs/DB00986ApprovedInvestigationalVet approved[A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090] … [L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium].
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results
Periciazine
go.drugbank.com/drugs/DB01608ApprovedPericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade. … It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system.
Selenious acid
go.drugbank.com/drugs/DB11127ApprovedSelenium (Se) has been demonstrated to prevent cancer in numerous animal models when administered selenium at levels exceeding the nutritional requirements. … The reports from such studies have heightened the interest in additional human selenium supplementation studies to validate the results in larger populations [L1918].
Mixtures: Addamel N, ADDAMEL NFomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnIt was discovered by scientists at the National Institutes of Health (NIH) and was first developed by _Isis Pharmaceuticals_ and subsequently licensed to _Novartis_ [A31990]. … The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development
Lixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]
Dapsone
go.drugbank.com/drugs/DB00250ApprovedInvestigationalA sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. … Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms.
Erlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalErlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.